Clinical characteristics and drug sensitivity in children with invasive pneumococcal disease: a multicenter study
WANG Cai-Yun1, CHEN Ying-Hu1, CHEN Xue-Jun2, XU Hong-Mei3, JING Chun-Mei4, DENG Ji-Kui5, ZHAO Rui-Zhen6, DENG Hui-Ling7, CAO San-Cheng8, YU Hui9, WANG Chuan-Qing10, WANG Ai-Min10, LIN Ai-Wei11, WANG Shi-Fu12, CAO Qing13, WANG Xing14, ZHANG Ting15, ZHANG Hong16, HAO Jian-Hua17, ZHANG Cong-Hui18
Department of Infectious Disease, Children's Hospital of Zhejiang University School of Medicine, Hangzhou 310052, China
Abstract Objective To study the clinical characteristics, drug sensitivity of isolated strains, and risk factors of drug resistance in children with invasive pneumococcal disease (IPD). Methods The clinical characteristics and drug sensitivity of the isolated strains of 246 hospitalized children with IPD in nine grade A tertiary children's hospitals from January 2016 to June 2018 were analyzed. Results Of the 246 children with IPD, there were 122 males and 124 females. Their ages ranged from 1 day to 14 years, and among them, 68 (27.6%) patients were less than 1 year old, 54 (22.0%) patients were 1 to 2 years old, 97 (39.4%) patients were 2 to 5 years old, and 27 (11.0%) patients were 5 to 14 years old. Pneumonia with sepsis was the most common infection type (58.5%, 144/246), followed by bloodstream infection without focus (19.9%, 49/246) and meningitis (15.0%, 37/246). Forty-nine (19.9%) patients had underlying diseases, and 160 (65.0%) had various risk factors for drug resistance. The isolated Streptococcus pneumoniae strains were 100% sensitive to vancomycin, linezolid, moxifloxacin, and levofloxacin, 90% sensitive to ertapenem, ofloxacin, and ceftriaxone, but had a low sensitivity to erythromycin (4.2%), clindamycin (7.9%), and tetracycline (6.3%). Conclusions IPD is more common in children under 5 years old, especially in those under 2 years old. Some children with IPD have underlying diseases, and most of the patients have various risk factors for drug resistance. Pneumonia with sepsis is the most common infection type. The isolated Streptococcus pneumoniae strains are highly sensitive to vancomycin, linezolid, moxifloxacin, levofloxacin, ertapenem, and ceftriaxone in children with IPD.
WANG Cai-Yun,CHEN Ying-Hu,CHEN Xue-Jun et al. Clinical characteristics and drug sensitivity in children with invasive pneumococcal disease: a multicenter study[J]. CJCP, 2019, 21(7): 644-649.
WANG Cai-Yun,CHEN Ying-Hu,CHEN Xue-Jun et al. Clinical characteristics and drug sensitivity in children with invasive pneumococcal disease: a multicenter study[J]. CJCP, 2019, 21(7): 644-649.
Kim L, McGee L, Tomczyk S, et al. Biological and epidemiological features of antibiotic-resistant streptococcus pneumoniae in pre-and post-conjugate vaccine eras:a United States perspective[J]. Clin Microbiol Rev, 2016, 29(3):525-552.
Berjohn CM, Fishman NO, Joffe MM, et al. Treatment and outcomes for patients with bacteremic pneumococcal pneumonia[J]. Medicine (Baltimore), 2008, 87(3):160-166.
[6]
Chen CJ, Lin CL, Chen YC, et al. Host and microbiologic factors associated with mortality in Taiwanese children with invasive pneumococcal diseases, 2001 to 2006[J]. Diagn Microbiol Infect Dis, 2009, 63(2):194-200.
[7]
Gómez-Barreto D, Espinosa-Monteros LE, López-Enríquez C, et al. Invasive pneumococcal disease in a third level pediatric hospital in Mexico City:epidemiology and mortality risk factors[J]. Salud Publica Mex, 2010, 52(5):391-397.
[8]
Alanee SR, McGee L, Jackson D, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults:an international study[J]. Clin Infect Dis, 2007, 45(1):46-51.
[9]
Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008:a systematic analysis[J]. Lancet, 2010, 375(9730):1969-1987.
[10]
Rajaratnam JK, Marcus JR, Flaxman AD, et al. Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010:a systematic analysis of progress towards Millennium Development Goal 4[J]. Lancet, 2010, 375(9730):1988-2008.
[11]
O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years:global estimates[J]. Lancet, 2009, 374(9693):893-902.
[12]
van den Heuvel D, Jansen MAE, Nasserinejad K, et al. Effects of nongenetic factors on immune cell dynamics in early childhood:The Generation R Study[J]. J Allergy Clin Immunol, 2017, 139(6):1923-1934.e17.
[13]
Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease:implications for conjugate vaccine formulation and use, part I[J]. Clin Infect Dis, 2000, 30(1):100-121.
[14]
Mulholland K, Temple B. Causes of death in children younger than 5 years in China in 2008[J]. Lancet, 2010, 376(9735):89.
[15]
Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report:Emerging Infection Program Network, Streptococcus pneumonia[EB/OL]. (2016)[2019-01-08].
Rose MA, Christopoulou D, Myint TT, et al. The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe[J]. Int J Clin Pract, 2014, 68(1):8-19.
Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries:an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study[J]. Antimicrob Agents Chemother, 2012, 56(3):1418-1426.
[21]
Oligbu G, Collins S, Sheppard CL, et al. Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006-2014[J]. Clin Infect Dis, 2017, 65(2):308-314.
